The role of pharmacoepidemiological studies in the market withdrawal of carisoprodol (Somadril®) in Europe

Norsk Epidemiologi

Volumn 18, Issue 2, 2008, Pages 167-172

  Bramness, Jørgen G ^a   Buajordet, Ingebjørg ^b   Skurtveit, Svetlana ^a,c  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b Norwegian Medicines Agency   (Norway)

^c UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Carisoprodol; Drug abuse; Impairment; Intoxication; Pharmacoepidemiology

Indexed keywords

CAFFEINE; CAFFEINE PLUS CARISOPRODOL PLUS PARACETAMOL; CARISOPRODOL; CHLORMEZANONE; CHLORMEZANONE PLUS PARACETAMOL; DRUG METABOLITE; LOBAC; MEPROBAMATE; NORGESIC; PARACETAMOL;

ANXIETY; DECISION MAKING; DRUG ABUSE; DRUG INTOXICATION; DRUG MARKETING; EUROPE; HEALTH CARE PERSONNEL; HUMAN; INSOMNIA; LOW BACK PAIN; MEDICAL SOCIETY; OBSERVATIONAL STUDY; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PSYCHOMOTOR DISORDER; REVIEW; RISK; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SIDE EFFECT; TRAFFIC ACCIDENT; TREMOR; WITHDRAWAL SYNDROME;

EID: 45549108019     PISSN: 08032491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Berger F. The muscle-relaxant and analgesic properties of carisoprodol. In: Miller J, ed. The pharmacology and clinical usefulness of carisoprodol. Detroit: Wayne State University Press, 1959.
2. Berger F, Hendley CD, Ludwig B, Lynes TE. Central depressant and anticonvulsant activity of compounds with 2-methyl-2-n-propyl-1,3-propanediol dicarbamate (Miltown). J Pharmacol Exp Ther 1956; 116: 337-42.
3. Berger F, Kletzkin M, Ludwig B, Margolin S. The history, chemistry, and pharmacology of carisoprodol. Ann N Y Acad Sci 1959; 86: 90-107.
4. Hollister LE. The pre-benzodiazepine era. J Psychoactive Drugs 1983; 15: 9-13.
5. Douglas J, Ludwig B, Schlosser A. The metabolic fate of carisoprodol in the dog. J Pharmacol Exp Ther 1962; 138: 21-7.
6. Brandslund I. A case of acute carisoprodol poisoning. Symptoms and metabolism. Ugeskr Lœger 1976; 138: 281-3.
7. Beermann B, Öhman B. Meprobamat - huvudmetabolit till karisoprodol. Läkartidn 1978; 75: 1962.
8. Lenz W. Malformations caused by drugs in pregnancy. Am J Dis Child 1966; 112: 99-106.
9. Vaeroy H, Abrahamsen A, Forre O, Kass E. Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp) versus placebo. Clin Rheumatol 1989; 8: 245-50.
10. Vaerøy H, Abrahamsen A, Førre Ø, Kristiansen P, Kåss E. Treatment of patients with fibromyalgia: a double blind clinical trial with Somadril Comp (carisprodol, paracetamol) versus placebo. Scand J Rheumatol 1988; 72: 38S.
11. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964; 192: 540-2.
12. Dahl E, Grenthe B, Lindqvist B. Comparsion of changes in pain threshold following oral administration of carisoprodol, acetylsalicyclic acid, and placebo. Swed Dent J'1981; 5: 77-80.
13. Soyka J, Maestripieri L. Soma compound (carisoprodol plus phenacetin and caffeine) in the treatment of acute, painful musculoskeletal conditions. Curr Ther Res 1979; 26: 165-80.
14. Miller AR. A comparative study of Parafon Forte tablets and Soma compound in the treatment of painful skeletal muscle conditions. Curr Ther Res Clin Exp 1976; 19: 444-50.
15. Cowan I, Mapes R. Carisoprodol in the management of musculoskeletal disorders. Ann Phys Med 1964; 7: 140-3.
16. Gallardo F, Molgo J, Miyazaki C, Rossi E. Carisoprodol in the treatment of myofascial pain-dysfunction syndrome. J Oral Surg 1975; 33: 655-8.
17. Cullen A. Carisoprodol (Soma) in acute back conditions: a double blind, randomized, placebo-controlled study. Curr Ther Res 1976; 20: 557-62.
18. Hindle T. Comparison of carisoprodol, butabarbital, and placebo in the treatment of low back syndrome. Calif Med 1912; 117: 7-11.
19. Baratta RR. A double-blind comparative study of carisoprodol, propoxyphene, and placebo in the management of low back syndrome. Curr Ther Res Clin Exp 1976; 20: 233-40.
20. Boyles W, Glassmann J, Soyka J. Management of acute muskuloskeletal conditions: thoracolumbar strain and sprain. A double-blind evaluation comparing the efficacy and safety of carisoprodol with diazepam. Today's Ther Trends 1983; 1: 1-16.
21. Rollings H, Glassmann J, Soyka J. Management of acute musculoskeletal conditions - thoracolumbar strain and sprain: a double-blind evaluation comparing the efficacy and safety of carisoprodol with cyclobenzadrine hydrochloride. Curr Ther Res 1982; 34: 917-28.
22. Waddell G, McIntosh A, Hutchinson A, Feder G, Lewis M. Low Back Pain Evidence Review, 2. edn. London: Royal College of General Practitioners, 1999.
23. Chou R, Peterson M, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage 2004; 28: 140-75.
24. van Tulder M, Touray T, Furlan A, Solway S, Bouter L. Muscle relaxants for non-specific low back pain (Cochrane review). The Cochrane library. Oxford: Update Software, 2003.
25. Tulder Mv, Waddell G. Akuta ländryggsbesvär - konservativ behandling. In: (SBU) Sbfmt, ed. Ont i ryggen, ont i nacken. En evidensbaserad kunskapssammanställning. Stockholm: SBU, 2000.
26. Vaglum P. Carisoprodat. Bivirkninger og smertestillende virkning bedomt ved et materiale fra praksis. Tidsskr Nor Lœgeforen 1962; 82.
27. Raffel S, Swink R, Lampton T. The influence of chlorphenesin carbamate and carisoprodol on psychological test scores. Curr Ther Res 1969; 11: 553-60.
28. Dalen P, Alvan G, Wakelkamp M, Olsen H. Formation of meprobamate from carisoprodol is catalysed by CYP2C19. Pharmacogenetics 1996; 6: 387-94.
29. Fernández-Rivas M, González Mancebo E. Urticaria to carisoprodol. Allergy 2002; 57: 55.
30. Balch H, Bain L. Evaluation of carisoprodol in the management of musculo-skeletal disorders. A controlled clinical trial. Ann Phys Med 1963; 7: 59-64.
31. Adams H, Kerzee T, Morehead C. Carisoprodol-related death in a child. J For Sci 1975; 20: 200-2.
32. Fraser H, Essig C, Wolbach A. Evaluation of carisoprodol and phenyramidol for addictiveness. National Institute of Mental Health, Addiction Research Centre 1961; http://www.unodc.org/unodc/en/bulletin/bulletin_1961-01- 01_4_page002.html.
33. Waterloo K, Flaten M, Simonsen T, Olsen H. The effect of carisoprodol on performance on repeatedly administered neuropsychological tests. Human Psychopharmacology 1997; 12: 393-6.
34. Flaten MA, Simonsen T, Zahlsen K, Aamo T, Sager G, Olsen H. Stimulant and relaxant drugs combined with stimulant and relaxant information: a study of active placebo. Psychopharmacology 2004; 176: 426-34.
35. Strom B. Pharmacoepidemiology. Chichester: John Wiley & Sons, 2000.
36. Logan BK, Case GA, Gordon AM. Carisoprodol, meprobamate, and driving impairment. J Forensic Sci 2000; 45: 619-23.
37. Schwilke EW, Sampaio dos Santos MI, Logan BK. Changing patterns of drug and alcohol use in fatally injured drivers in Washington State. J Forensic Sci 2006; 51: 1191-8.
38. Bramness JG, Skurtveit S, Grung M, Mørland J. Centrally acting muscle relaxants: abuse potential and traffic hazards. Tidsskr Nor Lœgeforen 2000; 120: 1966-9.
39. Bramness J, Skurtveit S, Mørland J. Impairment due to intake of carisoprodol. Drug Alcohol Depend 2004; 74: 311-8.
40. Bramness JG, Skurtveit S, Mørland J, Engeland A. The risk of traffic accidents after prescriptions of carisoprodol. Accid Anal Prev 2007; 39: 1050-5.
41. Backer RC, Zumwalt R, McFeeley P, Veasey S, Wohlenberg N. Carisoprodol concentrations from different anatomical sites: three overdose cases. J Anal Toxicol 1990; 14: 332-4.
42. Roberge RJ, Lin E, Krenzelok EP. Flumazenil reversal of carisoprodol (Soma) intoxication. J Emerg Med 2000; 18: 61-4.
43. Goldberg D. Carisoprodol toxicity. Military Medicine 1969; 134: 597-601.
44. Siddiqi M, Jennings C. A near-fatal overdose of carisoprodol (Soma): case report. J Toxicol Clin Toxicol 2004; 42: 239-40.
45. Blumberg A, Rosett H, Dobrow A. Severe hypotension reactions following meprobamate overdosage. Ann Intern Med 1959; 51: 607-12.
46. Lin JL, Lim PS, Lai BC, Lin WL. Continuous arteriovenous hemoperfusion in meprobamate poisoning. J Toxicol Clin Toxicol 1993; 31: 645-52.
47. Allen MD, Greenblatt DJ, Noel BJ. Meprobamate overdosage: a continuing problem. Clin Toxicol 1977; 11: 501-15.
48. Freund LG. Severe meprobamate intoxication treated by hemoperfusion over amberlite resin. Artif Organs 1981; 5: 80-1.
49. Graae J, Ladefoged J. [Severe meprobamate poisoning treated by hemodialysis and peritoneal dialysis]. Nord Med 1969; 81: 601-3.
50. Eeckhout E, Huyghens L, Loef B, Maes V, Sennesael J. Meprobamate poisoning, hypotension and the SwanGanz catheter. Intensive Care Med 1988; 14: 437-8.
51. Shane A, Hirsch S. Three cases of meprobamate poisoning. CMAJ 1956; 74: 908-9.
52. Stevens A. Hypotension due to meprobamate overdose. BMJ 1960; 1: 1029.
53. Ferguson M, Germanos S, Grace W. Meprobamate overdosage. A report on the management of five cases. Arch Intern Med 1960; 106: 127-9.
54. Bedson H. Coma due to meprobamate intoxication. Report of a case confirmed by chemical analysis. Lancet 1959; 273: 288-90.
55. Baird H, Menta D. Preliminary observations on the use of carisoprodol in infants and children. Correlation of plasma levels and clinical response. In: Miller J, ed. The pharmacology and clinical usefullness of carisoprodol. Detroit: Wayne State University Press, 1959.
56. Roth BA, Vinson DR, Kim S. Carisoprodol-induced myoclonic encephalopathy. J Toxicol Clin Toxicol 1998; 36: 609-12.
57. Bramness J, Sørlid H, Rudberg N, Mørland J, Jacobsen D. Carisoprodol intoxications and serotoninergic symptoms. J Toxicol Clin Toxicol 2005; 43: 39-46.
58. Substance Abuse and Mental Health Service Administration Office of Applied Studies. Emergency Department Trends From the Drug Abuse Warning Network, Final estimates 1995-2002. Rockville, MD: DAWN Series D-24, 2003.
59. Chung H, Park M, Hahn E, Choi H, Choi H, Lim M. Recent trends of drug abuse and drug-associated deaths in Korea. Ann N Y Acad Sci 2004; 1025: 458-64.
60. Høiseth G, Bramness JG, Christophersen AS, Mørland J. Carisoprodol intoxications: A retrospective study of forensic autopsy material from 1992-2003. Int J Legal Med 2001; 121: 403-9.
61. Høiseth G, Sørlid H, Bramness J. Carisoprodol Intoxications: contacts to the Norwegian Poisons information 1999-2004. J Clin Toxicol 2008 (in press).
62. Forrester MB. Drug identification calls from law enforcement received by Texas poison control centers, 2002-2004. J Toxicol Environ Health A 2006; 69: 2041-9.
63. Wyller T, Korsmo G, Gadeholt G. Carisoprodol-dependence. A prospective withdrawal study among prisoners. Tidsskr Nor Lœgeforen 1991; 111: 193-5.
64. Morse RM, Chua L. Carisoprodol dependence: a case report. Am J Drug Alcohol Abuse 1978; 5: 527-30.
65. Bailey DN, Briggs JR. Carisoprodol: an unrecognized drug of abuse. Am J Clin Pathol 2002; 117: 396-400.
66. Littrell RA, Sage T, Miller W. Meprobamate dependence secondary to carisoprodol (Soma) use. Am J Drug Alcohol Abuse 1993; 19: 133-4.
67. Elder NC. Abuse of skeletal muscle relaxants. Am Fam Physician 1991; 44: 1223-6.
68. Reeves RR, Beddingfield JJ, Mack JE. Carisoprodol withdrawal syndrome. Pharmacother 2004; 24: 1804-6.
69. Littrell RA, Hayes LR, Stillner V. Carisoprodol (Soma): a new and cautious perspective on an old agent. South Med J 1993; 86: 753-6.
70. Reeves RR, Parker JD. Somatic dysfunction during carisoprodol cessation: evidence for a carisoprodol withdrawal syndrome. J Am Osteopath Assoc 2003; 103: 75-80.
71. Reeves RR, Carter OS, Pinkofsky HB, Struve FA, Bennett DM. Carisoprodol (soma): abuse potential and physician unawareness. J Addict Dis 1999; 18: 51-6.
72. Bramness JG, Furu K, Engeland A, Skurtveit S. Carisoprodol use and abuse in Norway. A pharmacoepidemiological study. Br J Clin Pharmacol 2001; 64: 210-8.
73. Hallas J, Støvring H. Templates for analysis of individual-level prescription data. Basic Clin Pharmacol Toxicol 2006; 98: 260-5.
74. Gaist D, Andersen M, Aarup AL, Hallas J, Gram LF. Use of sumatriptan in Denmark in 1994-5: an epidemiological analysis of nationwide prescription data. Br J Clin Pharmacol 1997; 43: 429-33.
75. Rygnestad T, Aamo T. The use of carisoprodol (Somadril). What does Dumex take us for? Tidsskr Nor Lœgeforen 1997; 117: 1004-5.
76. Gadeholt G. Somadril Comp. "Dumex" Marketing authorisation withdrawn. News from the Norwegian Medicinal Authorities 1995; 4.
77. Ronning M. Drug consumption in Norway 1996-2000. Oslo: Norwegian Medicinal Depot, 2001.
78. Reiestad F, Fagerlund B. [Is carisoprodol justified as a muscle relaxant?]. Tidsskr Nor Lœgeforen 2000; 120: 2041-2.
79. Bramness JG. The pharmacokinetics, CYP2C19 pharmacogenetics and psychomotor impairment of the centrally acting muscle relaxant carisoprodol. Oslo: University of Oslo, 2005.
80. Bramness J, Skurtveit S, Gulliksen M, Breilid H, Steen V, Morland J. The influence of CYP2C19 genotype and the use of oral contraceptives on the pharmacokinetics of carisoprodol i healthy human subjects. Eur J Clin Pharmacol 2005; 61: 499-506.
81. Bramness JG, Skurtveit S, Fauske L, Grung M, Molven A, Morland J, Steen VM. Association between blood carisoprodol: meprobamate concentration ratios and CYP2C19 genotype in carisoprodol-drugged drivers: decreased metabolic capacity in heterozygous CYP2C19*1/CYP2C19*2 subjects? Pharmacogenetics 2003; 13: 383-8.
82. Buajordet I, Madsen S. [Somadril recalled in Norway]. Tidsskr Nor Lœgeforen 2007; 127: 1397.
83. Alme T. B-preparat under falsk flagg. Dagens Medisin, 19 April 2007.